Literature DB >> 9746613

Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection.

J Rivera1, M Feldmesser, M Cammer, A Casadevall.   

Abstract

In studies of murine infection, the capsule thickness of Cryptococcus neoformans varied depending on the organ. The relative order of thickness was as follows: lung > brain > in vitro isolates. The differences in capsule thickness suggest that there are organ-related differences in the expression of genes responsible for capsule thickness.

Entities:  

Mesh：

Year:  1998        PMID： 9746613      PMCID： PMC108624     

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  15 in total

1.  A rapid fluorescent assay to distinguish attached from phagocytized yeast particles.

Authors:  S M Levitz; D J DiBenedetto; R D Diamond
Journal:  J Immunol Methods       Date:  1987-07-16       Impact factor: 2.303

2.  Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.

Authors:  M Feldmesser; A Casadevall
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

3.  The distribution of iron in the brain: a phylogenetic analysis using iron histochemistry.

Authors:  G L Erb; D L Osterbur; S M LeVine
Journal:  Brain Res Dev Brain Res       Date:  1996-05-31

4.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Histochemical distribution of non-haem iron in the human brain.

Authors:  C M Morris; J M Candy; A E Oakley; C A Bloxham; J A Edwardson
Journal:  Acta Anat (Basel)       Date:  1992

Review 6.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

Authors:  A Casadevall; J Mukherjee; M D Scharff
Journal:  J Immunol Methods       Date:  1992-09-18       Impact factor: 2.303

8.  Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City.

Authors:  B P Currie; A Casadevall
Journal:  Clin Infect Dis       Date:  1994-12       Impact factor: 9.079

9.  The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.

Authors:  A Casadevall; M D Scharff
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

10.  Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.

Authors:  G Nussbaum; W Cleare; A Casadevall; M D Scharff; P Valadon
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307
View more
  63 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

Review 2.  Role of phagocytosis in the virulence of Cryptococcus neoformans.

Authors:  Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2004-10

3.  Does the Capsule Interfere with Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Cryptococcus neoformans and Cryptococcus gattii?

Authors:  Danilo Y Thomaz; Rafaella C Grenfell; Monica S M Vidal; Mauro C Giudice; Gilda M B Del Negro; Luiz Juliano; Gil Benard; João N de Almeida Júnior
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

4.  Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.

Authors:  Michelle E Maxson; Ekaterina Dadachova; Arturo Casadevall; Oscar Zaragoza
Journal:  Eukaryot Cell       Date:  2006-11-17

5.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

6.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

7.  Neurovirulence of Cryptococcus neoformans determined by time course of capsule accumulation and total volume of capsule in the brain.

Authors:  A Pool; L Lowder; Y Wu; K Forrester; J Rumbaugh
Journal:  J Neurovirol       Date:  2013-06-04       Impact factor: 2.643

8.  Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.

Authors:  Leonardo Nimrichter; Susana Frases; Leonardo P Cinelli; Nathan B Viana; Antonio Nakouzi; Luiz R Travassos; Arturo Casadevall; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2007-06-15

9.  Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection.

Authors:  Ekaterina Dadachova; Antonio Nakouzi; Ruth A Bryan; Arturo Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

10.  Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct.

Authors:  Priscila C Albuquerque; Fernanda L Fonseca; Fabianno F Dutra; Marcelo T Bozza; Susana Frases; Arturo Casadevall; Marcio L Rodrigues
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.